The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

Giovanni Tomasello, Antonella Marino Gammazza, Attilio Ignazio Lo Monte, Vincenzo Davide Palumbo, Giuseppe Damiano, Francesco Carini, Salvatore Buscemi, Marcello Romeo, Antonella Marino Gammazza, Alice Gerges-Geagea, Giovanni Tomasello, Vincenzo Davide Palumbo, Abdo Jurjus, Provvidenza Damiani

Risultato della ricerca: Article

16 Citazioni (Scopus)

Abstract

Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
Lingua originaleEnglish
pagine (da-a)372-377
Numero di pagine6
RivistaBIOMEDICAL PAPERS OF THE THE FACULTY OF MEDICINE OF PALACKÝ UNIVERSITY, OLOMOUC CZECH REPUBLIC
Volume160
Stato di pubblicazionePublished - 2016

Fingerprint

Probiotics
Ulcerative Colitis
Mesalamine
Lactobacillus acidophilus
Bifidobacterium
Inflammatory Bowel Diseases
Oral Administration
Anti-Inflammatory Agents
Therapeutics
Dysbiosis
Weapons
Pharmaceutical Preparations
Clinical Studies
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cita questo

@article{5a332ad06e144b97914e0829a6928d30,
title = "The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study",
abstract = "Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.",
author = "Giovanni Tomasello and {Marino Gammazza}, Antonella and {Lo Monte}, {Attilio Ignazio} and Palumbo, {Vincenzo Davide} and Giuseppe Damiano and Francesco Carini and Salvatore Buscemi and Marcello Romeo and Gammazza, {Antonella Marino} and Alice Gerges-Geagea and Giovanni Tomasello and Palumbo, {Vincenzo Davide} and Abdo Jurjus and Provvidenza Damiani",
year = "2016",
language = "English",
volume = "160",
pages = "372--377",
journal = "Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia",
issn = "1213-8118",
publisher = "Palacky University",

}

TY - JOUR

T1 - The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

AU - Tomasello, Giovanni

AU - Marino Gammazza, Antonella

AU - Lo Monte, Attilio Ignazio

AU - Palumbo, Vincenzo Davide

AU - Damiano, Giuseppe

AU - Carini, Francesco

AU - Buscemi, Salvatore

AU - Romeo, Marcello

AU - Gammazza, Antonella Marino

AU - Gerges-Geagea, Alice

AU - Tomasello, Giovanni

AU - Palumbo, Vincenzo Davide

AU - Jurjus, Abdo

AU - Damiani, Provvidenza

PY - 2016

Y1 - 2016

N2 - Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

AB - Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

UR - http://hdl.handle.net/10447/202597

UR - http://biomed.papers.upol.cz/doi/10.5507/bp.2016.044.pdf

M3 - Article

VL - 160

SP - 372

EP - 377

JO - Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia

JF - Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia

SN - 1213-8118

ER -